Table 2.
Characteristics of adult patients.
| Characteristics | Overall (n = 131) | Responders (n = 77) | Non-Responders (n = 54) | p Value |
|---|---|---|---|---|
| Sex | ||||
| Male, n (%) | 66 (50.4%) | 41 (62.1%) | 25 (37.9%) | 0.480 |
| Female, n (%) | 65 (49.6%) | 36 (55.4%) | 29 (44.6%) | |
| Age (years) | ||||
| At diagnosis, median (IQR, range) | 27.2 (16.4; 10.8–76.7) | 27.7 (18.2; 10.8–76.7) | 26.7 (15.9; 11.7–58.7) | 0.359 |
| At start of treatment, median (IQR, range) | 37.4 (18.5; 12.5–81.4) | 36.6 (19; 12.5–81.4) | 35.5 (18.2; 16.2–64.5) | 0.818 |
| First or second biological treatment | ||||
| 1st, n (%) | 119 (90.8%) | 73 (60.3%) | 48 (39.7%) | 0.317 |
| 2nd, n (%) | 12 (9.2%) | 4 (40%) | 6 (60%) | |
| Concomitant immunomodulator (n = 128) | ||||
| Yes, n (%) | 68 (51.9%) | 47 (69.1%) | 21 (30.9%) | 0.045 |
| No, n (%) | 60 (45.8%) | 30 (50%) | 30 (50%) | |
| Type of immunotherapy | ||||
| Azathioprine | 54 (79.4%) | 39 (72.2%) | 15 (27.8%) | 0.870 |
| Mercaptopurine | 4 (5.9%) | 4 (100%) | 0 (0%) | |
| Methotrexate | 7 (10.3%) | 2 (28.6%) | 5 (71.4%) | |
| Mycophenolate | 3 (4.4%) | 2 (66.7%) | 1 (33.3%) | |
Bold, p value < 0.05; IQR, Interquartile range.